专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1997029128A1 GPIb-LIPID COMPLEX AND USES THEREOF 审中-公开
标题翻译： GPIb-LIPID复合物及其用途
公开(公告)号：WO1997029128A1
公开(公告)日：1997-08-14
申请号：PCT/JP1997000284
申请日：1997-02-06
申请人： THE GREEN CROSS CORPORATION , MATSUDA, Hiroshi , KAMIDE, Kaeko , AMATSUJI, Yasuo , IMAGAWA, Takashi , IKEDA, Yasuo , MURATA, Mitsuru
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07K14/705
CPC分类号： A61K9/1271 , A61K38/00 , A61K47/62 , A61K47/6911 , C07K14/705 , C07K14/70596
摘要： A complex comprising GPIb and a lipid having a functional group. As it can bind with vWF and can form aggregates, it is useful as a platelet substitute, medicines for preventing and curing vascular lesion, vascular injury and thrombosis, a diagnostic agent for vWF deficiency, biological-medical reagents, and reagents for screening platelet aggregation inhibitors and antithrombotic agents. Also, as it is apt to specifically concentrate around the lesioned vascular parts, it is useful as diagnostic agents for testing vascular lesion, injured parts and thrombosed parts or remedies therefor.
摘要翻译：包含GPIb和具有官能团的脂质的复合物。由于它可以与vWF结合并且可以形成聚集体，它可用作血小板替代物，用于预防和治疗血管损伤，血管损伤和血栓形成的药物，用于vWF缺陷的诊断剂，生物医学试剂和用于筛选血小板聚集的试剂抑制剂和抗血栓形成剂。此外，由于易于特异性地集中在损伤的血管部分周围，因此它可用作测试血管损伤，受伤部件和血栓部位的诊断剂或其补救措施。

2. 发明申请

WO1994001393A1 NOVEL CHELATING AGENT, COMPLEX COMPOUND COMPOSED OF SAID AGENT AND METALLIC ATOM, AND DIAGNOSTIC AGENT CONTAINING SAID COMPOUND 审中-公开
标题翻译：新型螯合剂，由化合物和金属原子组成的复合化合物，以及含有化合物的诊断试剂
公开(公告)号：WO1994001393A1
公开(公告)日：1994-01-20
申请号：PCT/JP1993000331
申请日：1993-03-22
申请人： THE GREEN CROSS CORPORATION , MORI, Fumio , OKANO, Tadashi , MURAKAMI, Kazuki , SHINTOME, Masakazu , MUKAI, Hiromichi , MIYAGI, Ikuko , IMAGAWA, Takashi , KIM, Sang-Won , MARUKAWA, Taro , KOZUKA, Takahiro
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07C229/06
CPC分类号： C07C229/16 , A61K49/06 , C07C237/04 , Y10T436/24
摘要： A compound represented by general formula (I), a complex compound composed of the above compound and a metallic atom, and a diagnostic agent containing the complex compound, wherein m represents an integer of 1 to 3, R1 and R2 may be the same or different from each other and each represents hydrogen or lower alkyl, and R3, R4, R5 and R6 may be the same or different from one another and each represents hydroxy or (II), wherein n represents 0 or 1, X represents -NH- or -O-, Y represents alkylene, A represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and B represents alkyl or alkenyl, provided that two or three of the groups R3, R4, R5 and R6 are hydroxy and that when two of them are hydroxy groups, then the cases where R3 and R5 are hydroxy and where R4 and R6 are hydroxy are excluded. The first-mentioned compound is useful as a chelating agent and the complex compound has excellent characteristics as a contrast medium for diagnostic imaging.
摘要翻译：由通式（I）表示的化合物，由上述化合物和金属原子组成的络合物和含有配位化合物的诊断剂，其中m表示1〜3的整数，R1和R2可以相同或相同，彼此不同，各自表示氢或低级烷基，R 3，R 4，R 5和R 6可以彼此相同或不同，并且各自表示羟基或（II），其中n表示0或1，X表示-NH- 或-O-，Y表示亚烷基，A表示氢，低级烷基，低级烷氧基，卤素或三氟甲基，B表示烷基或烯基，条件是R3，R4，R5和R6中的两个或三个为羟基，其中两个是羟基，则排除R3和R5是羟基，R4和R6是羟基的情况。首先提及的化合物可用作螯合剂，并且络合物具有作为诊断成像的造影剂的优异特性。

3. 发明申请

WO1990012576A1 LIQUID PROSTAGLANDIN COMPOSITION 审中-公开
标题翻译：液体PROSTAGLANDIN组合物
公开(公告)号：WO1990012576A1
公开(公告)日：1990-11-01
申请号：PCT/JP1990000525
申请日：1990-04-23
申请人： THE GREEN CROSS CORPORATION , IMAGAWA, Takashi;
发明人： THE GREEN CROSS CORPORATION
IPC分类号： A61K31/557
CPC分类号： A61K9/0019 , A61K9/1075 , A61K31/557 , A61K47/10
摘要： A liquid composition comprising prostaglandin and a polyoxyethylene-polyoxypropylene copolymer having a molecular weight of 1,000 to 20,000. The stability of the prostaglandin can be remarkably improved by the use of the above-specified copolymer.
摘要翻译：包含前列腺素的液体组合物和分子量为1,000〜20,000的聚氧乙烯 - 聚氧丙烯共聚物。通过使用上述规定的共聚物可以显着提高前列腺素的稳定性。

4. 发明申请

WO1998018492A1 METHOD OF INHIBITING DRUG PRECIPITATION 审中-公开
标题翻译：抑制药物降解的方法
公开(公告)号：WO1998018492A1
公开(公告)日：1998-05-07
申请号：PCT/JP1997003859
申请日：1997-10-23
申请人： THE GREEN CROSS CORPORATION , KODAIRA, Hideto , KIDO, Takae , NAWA, Yoshihito , MUNECHIKA, Koji , UEDA, Yasuo
发明人： THE GREEN CROSS CORPORATION
IPC分类号： A61K47/14
CPC分类号： A61K9/127 , A61K9/0019 , A61K9/1075 , A61K47/14 , A61K47/24
摘要： A method of inhibiting the precipitation of an acidic or basic drug which is liable to cause precipitation in aqueous solutions, such as a transfusion, by blending the drug with at least one ingredient selected among phospholipids, glycerides and synthetic surfactants, whereby it is possible to inhibit the precipitation of the drug liable to cause precipitation as a result of solubility lowering due to a pH change. Accordingly, it is possible to administer such a drug to a patient under the physiological pH conditions by mixing the drug with a transfusion having such an electrolyte composition as to fit the condition of the patient.
摘要翻译：通过将药物与选自磷脂，甘油酯和合成表面活性剂中的至少一种成分混合，抑制易于在水溶液中析出的酸性或碱性药物的沉淀的方法，例如输血，由此可以抑制由于pH变化引起的溶解性降低的结果，容易引起沉淀的药物的沉淀。因此，通过将药物与具有适合患者状况的电解质组成的输液混合，可以在生理pH条件下向患者施用这种药物。

5. 发明申请

WO1996033974A1 HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME 审中-公开
标题翻译：杂环酰胺化合物及其药物用途
公开(公告)号：WO1996033974A1
公开(公告)日：1996-10-31
申请号：PCT/JP1996001171
申请日：1996-04-26
申请人： THE GREEN CROSS CORPORATION , AKAHOSHI, Fumihiko , YOSHIMURA, Takuya , EDA, Masahiro , ASHIMORI, Atsuyuki , FUKUYAMA, Hajime , NAKAJIMA, Masahide , IMADA, Teruaki , OKUNISHI, Hideki , MIYAZAKI, Mizuo
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07D213/64
CPC分类号： C07D213/73 , C07D213/75 , C07D239/47
摘要： Heterocyclic compounds represented by general formula (I) or pharmacologically acceptable salts of the same and a medicinal composition comprising the same, wherein each symbol has the meaning as defined in the specification. The heterocyclic amide compounds and pharmacologically acceptable salt thereof have excellent effects of inhibiting chymases on mammals including human being and can be orally or parenterally administered. Thus they are useful as a chymase inhibitor and can be used in the prevention and treatment of various diseases caused by chymases such as those caused by angiotensin II.
摘要翻译：由通式（I）表示的杂环化合物或其药理学上可接受的盐及包含其的药用组合物，其中每个符号具有说明书中定义的含义。杂环酰胺化合物及其药理学上可接受的盐具有抑制糜烂酶对包括人在内的哺乳动物的口服或肠胃外给药的优异效果。因此，它们可用作胃促胰酶抑制剂，并且可用于预防和治疗由糜酶如由血管紧张素II引起的各种疾病引起的各种疾病。

6. 发明申请

WO1996003503A1 PROCESS FOR PRODUCING URINARY TRYPSIN INHIBITOR AND DOMAINS THEREOF, NOVEL POLYPEPTIDE RELATED TO THE BOTH, AND PROCESS FOR PRODUCING THE POLYPEPTIDE 审中-公开
标题翻译：用于生产尿素抑制剂及其领域的方法，与两相关的新型多肽，以及生产多肽的方法
公开(公告)号：WO1996003503A1
公开(公告)日：1996-02-08
申请号：PCT/JP1995001449
申请日：1995-07-21
申请人： THE GREEN CROSS CORPORATION , IDENO, Shoji , GOTO, Takashi , HORII, Hajime
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C12N15/12
CPC分类号： C07K14/8103 , A61K38/00
摘要： A process for producing a urinary human trypsin inhibitor (UTI) and domains thereof by using a yeast of the genus Pichia as the host cell; an expression system related thereto; a novel polypeptide at least having the amino acid sequence represented by formula (I) in the specification; a DNA coding for the same; an expression vector containing the DNA; a transformant containing the vector; and a process for producing the polypeptide. The above UTI, expression system of each domain thereof, and process for producing the UTI and domains thereof enable UTI and domains thereof to be mass-produced readily and efficiently. The use of the expression system facilitates the preparation of variants or derivatives of UTI and so forth and contributes to the development of novel medicines such as a protease inhibitor. The invention also provides a novel useful polypeptide which is more excellent in elastase inhibitory activity than natural UTI and can be mass-produced.
摘要翻译：通过使用毕赤酵母属的酵母作为宿主细胞来制备尿胰蛋白酶抑制剂（UTI）及其结构域的方法; 与此有关的表达制度; 至少具有说明书中由式（I）表示的氨基酸序列的新型多肽; 编码相同的DNA; 含有DNA的表达载体; 含有载体的转化体以及产生该多肽的方法。上述UTI，其每个结构域的表达系统，以及UTI及其结构域的制备方法使得UTI及其结构域容易且有效地批量生产。表达系统的使用促进了UTI等变体或衍生物的制备，并有助于新型药物如蛋白酶抑制剂的开发。本发明还提供了一种与天然UTI相比弹性蛋白酶抑制活性更优异的新型有用多肽，可以批量生产。

7. 发明申请

WO1995007898A1 SUCCINAMIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF 审中-公开
标题翻译：磺胺酸化合物，其生产方法及其用途
公开(公告)号：WO1995007898A1
公开(公告)日：1995-03-23
申请号：PCT/JP1994001266
申请日：1994-08-01
申请人： SENJU PHARMACEUTICAL CO., LTD. , THE GREEN CROSS CORPORATION , HOSONO, Hiroshi , NISHIO, Toshiyuki , ISHIKAWA, Hiromichi , NAKAMURA, Yoshiyuki , MATSUI, Tetsuo
发明人： SENJU PHARMACEUTICAL CO., LTD. , THE GREEN CROSS CORPORATION
IPC分类号： C07D277/64
CPC分类号： C07D277/64
摘要： A novel succinamic acid compound represented by general formula (1) or a pharmaceutically acceptable salt thereof; a preventive and/or a remedy for complications of diabetes containing the compound or the salt as the active ingredient; an aldose reductase inhibitor containing the compound or the salt as the active ingredient; and a process for producing the compound or the salt. In said formula, R represents alkyl or lower alkenyl, and R represents carboxyl which may be esterified. The invention compound (1) and the salt have a potent aldose reductase inhibitor activity on mammals including humans and an excellent safety, and hence are useful as a remedy for therapeutic treatment of complications of diabetes, such as failure of corneal lesion union, cataract, neurosis, retinopathy and nephropathy, especially cataract and neurosis. The invention process can provide the invention compounds having such a usefulness efficiently.
摘要翻译：一种由通式（1）表示的新型琥珀酰胺酸化合物或其药学上可接受的盐; 包含化合物或盐作为活性成分的糖尿病并发症的预防和/或补救措施; 含有该化合物或该盐作为有效成分的醛糖还原酶抑制剂; 以及该化合物或其盐的制造方法。在所述式中，R 1表示烷基或低级烯基，R 2表示可被酯化的羧基。本发明化合物（1）和盐具有对包括人类在内的哺乳动物有效的醛糖还原酶抑制剂活性，并且具有优异的安全性，因此可用作治疗糖尿病并发症的治疗方法，例如角膜损伤联合失败，白内障，神经症，视网膜病变和肾病，特别是白内障和神经症。本发明方法可以有效地提供具有这种有效性的本发明化合物。

8. 发明申请

WO1994025059A1 NUTRITIONAL TRANSFUSION FOR PERIPHERAL VEIN ADMINISTRATION 审中-公开
标题翻译：营养管理外周血管理
公开(公告)号：WO1994025059A1
公开(公告)日：1994-11-10
申请号：PCT/JP1994000713
申请日：1994-04-27
申请人： THE GREEN CROSS CORPORATION , KIKUCHI, Masahiro , OKUTANI, Yoshihiko , INOUE, Tadaaki , MURASHIMA, Ryoichiro , ABE, Shunichi , KOSHIBA, Hiroshi , SHIBATA, Hiroshi , ISHII, Shunichiro , KAWABATA, Yoshiyasu , YOKOYAMA, Kazumasa
发明人： THE GREEN CROSS CORPORATION
IPC分类号： A61K37/22
CPC分类号： A61K9/0029
摘要： A nutritional transfusion that can be administered via peripheral veins and is improved in stability and conservability. It contains a saccharide, an amino acid, an electrolyte and a fat emulsion each in a specified proportion and has specified pH value and titratable acidity. It has a good conservability because it is free from precipitation and denaturation in spite of its composition comprising the above various components. Further it is free from the problem of angialgia or the like even when administered via peripheral veins, since it has a specified pH value and a low titratable acidity.
摘要翻译：营养输液可通过外周静脉施用，并且稳定性和保守性得到改善。它含有糖，氨基酸，电解质和脂肪乳剂，每一种都以规定的比例，具有规定的pH值和可滴定的酸度。它具有良好的保守性，因为尽管其组合物包含上述各种组分，但它没有沉淀和变性。此外，即使通过周围静脉施用时，也没有血管紧张素等的问题，因为其具有指定的pH值和低滴定酸度。

9. 发明申请

WO1994021688A1 METHOD OF DECOLORING HUMAN SERUM ALBUMIN 审中-公开
标题翻译：分解人血清白蛋白的方法
公开(公告)号：WO1994021688A1
公开(公告)日：1994-09-29
申请号：PCT/JP1994000459
申请日：1994-03-22
申请人： THE GREEN CROSS CORPORATION , SUMI, Akinori , NODA, Munehiro , OHTANI, Wataru , OHMURA, Takao
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07K15/06
CPC分类号： C07K14/625 , A61K38/00
摘要： A human serum albumin (HSA) derived from the plasma is treated with a chelate resin, preferably one having a nitrogenous exchange group as the ligand, in the step of purifying HSA, particularly preferably in the final stage thereof. This method serves to remove some kind of colored components of the plasma, such as bilirubin, which have been difficult to remove satisfactorily by the conventional method of purifying plasma-derived HSA. It is particularly useful for removing colored components having an absorption wavelength around 450 nm, i.e., red-colored components, thus giving HSA sufficiently reduced in coloration.
摘要翻译：在纯化HSA的步骤中，特别优选在最后阶段，用螯合树脂（优选具有含氮交换基团的螯合树脂作为配体）处理来源于血浆的人血清白蛋白（HSA）。该方法用于除去血浆衍生的HSA的常规方法难以令人满意地除去血浆中某些有色组分，如胆红素。特别有用于除去具有约450nm的吸收波长的有色成分，即红色成分，从而使HSA的着色充分降低。

10. 发明申请

WO1994003626A1 METHOD OF HIGHLY PURIFYING HUMAN SERUM ALBUMIN 审中-公开
标题翻译：高效清洗人血清白蛋白的方法
公开(公告)号：WO1994003626A1
公开(公告)日：1994-02-17
申请号：PCT/JP1993001048
申请日：1993-07-26
申请人： THE GREEN CROSS CORPORATION , FULUHATA, Naoto; , SUMI, kinori; , OHMURA, Takao;
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C12P21/02
CPC分类号： C07K14/765 , C12N15/815
摘要： A method of highly purifying human serum albumin (HSA) which comprises bringing a fraction containing HSA produced by gene manipulation into contact with a chelate chromatography carrier having copper ions combined therewith and eluting the HSA adsorbed on the carrier by using a buffer having a pH of 5 to 7 and containing ammonium chloride as an antagonist. This method can provide a highly pure HSA free from yeast-origin components which have been dificult to remove satisfactorily by the conventional method of purifying HSA produced by gene manipulation.
摘要翻译：一种高纯度人血清白蛋白（HSA）的方法，其包括使含有通过基因操作产生的HSA的级分与与其结合的铜离子的螯合色谱载体接触，并通过使用pH为 5〜7，含有氯化铵作为拮抗剂。该方法可以提供不含酵母来源成分的高纯度HSA，这些组分通过纯化通过基因操作产生的HSA的常规方法令人满意地除去。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式